Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-01-31 4:10 pm Purchase | 2023-12-31 | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 6,375,000 9.800% | 6,375,000 (New Position) | Filing History |
2024-01-31 4:10 pm Sale | 2023-12-31 | 13G | Autolus Therapeutics plc AUTL | Tetragon Financial Management LP | 8,000,000 4.600% | -1,461,883 (-15.45%) | Filing History |
2023-03-20 09:13 am Purchase | 2023-03-09 | 13G | Autolus Therapeutics plc AUTL | Tetragon Financial Management LP | 9,461,883 5.500% | 9,461,883 (New Position) | Filing History |
2023-01-31 4:15 pm Purchase | 2022-12-31 | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 266,667 6.200% | 20,000 (+8.11%) | Filing History |
2022-12-08 12:42 pm Unchanged | 2022-11-28 | 13D | Applied Genetic Technologies Corporation AGTC | Tetragon Financial Management LP | 0 0.000% | 0 (Unchanged) | Filing History |
2022-03-21 11:10 am Purchase | 2022-03-10 | 13G | Freeline Therapeutics Holdings plc FRLN | Tetragon Financial Management LP | 246,667 6.100% | 246,667 (New Position) | Filing History |